Manuel Grossmann

Founding Partner Amino Collective | Backing Frontier Health & Bio Founders

📍 Germany🔄 Updated October 2026💼 7 investments📅 5 years investing🗓 Last invested Aug 2024
VC🌍 Germany
7
Total investments
3
Early stage
1
Mid stage
0
Late stage
5y
Years active

Portfolio

7 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Seed Investor
Aug 2024
Tandem provides a clinician copilot that enables clinicians to focus on providing care, instead of on administrative tasks. Our ambient scribe listens during the patient consultation, transcribes it, and automatically generates a draft medical note that can seamlessly be transferred to your medical record system. Tandems copilot fully follows GDPR and local patient data laws.
Seed Investor
Jul 2022
Portal is revolutionising biosensing by bringing precise and universal proteomics and metabolomics to the bench-top. Proteins are the functional unit of biology, involved in every pathway and reaction, every synthesis and chemical modification, that make life possible. To understand proteins and metabolites is to understand ourselves: how we work, our health, how our bodies respond to treatments and interventions. Nanopores are nature’s biosensor — molecular devices with an exquisite sensitivity honed over billions of years of evolution. By using our deep expertise in bioengineering and machine-learning to improve on the remarkable properties of biological nanopores, and combining with our unique microelectronics, our products provide category-defining biological insight on a single-molecule basis. Portal, Portal Biotech and Portal Biotechnologies are trading names of Portal Biotechnology Limited.
Seed Investor
Mar 2022
We believe Cells can theoretically produce almost anything, from fabrics to food, fuel and medicines. Designing cell-factories is hard, but our tools and machine-learning models can make it easier. Our mission is to ultimately help replace traditional farms and factories for a more sustainable world. Jobs: https://jobs.cradle.bio
early stageBiotechnology
Seed Investor
Nov 2021
Seqera is on a mission to simplify complex data analysis pipelines in the cloud. We provide software that enables developers and data scientists to create and deploy data applications in any environment. Our core, open-source technology Nextflow transforms the building of massively scalable and distributed computing solutions. Seqera is now empowering customers across pharma, genomics and biotech to break with the status quo of closed-platforms and custom scripts to embrace the future of cloud.
Seed Investor
Nov 2021
Lindus is an Accountable Research Organization, engineered to give biotech and pharmaceutical sponsors confidence and control to generate clinical data on time and on budget. In the last 3 years, Lindus has executed over 45 full-scope trials across cardiometabolic, respiratory, psychiatry, dermatology, womens health, and diagnostics. Behind each study is an integrated model spanning feasibility, central enrollment infrastructure, and flexible site models. Trials run on Citrus™, an AI-native trial operating system, and are governed by performance-based contracts with milestone-based payments. 82% of Lindus executed trials completed enrollment on or ahead of our proposed timeline. The company is backed by Dr. Bob Langer, Peter Thiel, and Dr. Tim Garnett.
Seed Investor
Oct 2021
Developers at leading digital health companies, from Metabolic clinics to Longevity, use Junction to remotely access granular health data from wearables and lab tests. Junctions platform simplifies the integration and management of API connections with wearables, medical devices, and lab services. From test ordering to results retrieval, Vital handles it all—coordinating across 5,000+ walk-in testing centers, shipping lab kits directly to patients, and scheduling mobile phlebotomist visits. This streamlined process reduces operational burdens, allowing you to focus on delivering high-impact solutions. Junction supports a wide range of healthcare applications, including: - Correlating key biomarkers like HRV and sleep to track recovery progress - Managing chronic conditions with integrated support for blood pressure monitors, CGMs, and wearables - Scaling data collection for clinical trials across a distributed population - Personalizing treatment plans with wearables data and cost-effective specialty lab testing across 50 states Junction helps you access key insights, personalize treatment programs, and improve health outcomes across multiple sectors, all through a single universal API.
Seed Investor
Feb 2021
The next generation care enablement platform - with everything care teams need to resolve caseload quickly and safely.
Experience · 9 entries
All (9)
Investments (7)
2024
Seed Investor
Aug 2024
Tandem provides a clinician copilot that enables clinicians to focus on providing care, instead of on administrative tasks. Our ambient scribe listens during the patient consultation, transcribes it, and automatically generates a draft medical note that can seamlessly be transferred to your medical record system. Tandems copilot fully follows GDPR and local patient data laws.
2022
Seed Investor
Jul 2022
Portal is revolutionising biosensing by bringing precise and universal proteomics and metabolomics to the bench-top. Proteins are the functional unit of biology, involved in every pathway and reaction, every synthesis and chemical modification, that make life possible. To understand proteins and metabolites is to understand ourselves: how we work, our health, how our bodies respond to treatments and interventions. Nanopores are nature’s biosensor — molecular devices with an exquisite sensitivity honed over billions of years of evolution. By using our deep expertise in bioengineering and machine-learning to improve on the remarkable properties of biological nanopores, and combining with our unique microelectronics, our products provide category-defining biological insight on a single-molecule basis. Portal, Portal Biotech and Portal Biotechnologies are trading names of Portal Biotechnology Limited.
Seed Investor
Mar 2022
We believe Cells can theoretically produce almost anything, from fabrics to food, fuel and medicines. Designing cell-factories is hard, but our tools and machine-learning models can make it easier. Our mission is to ultimately help replace traditional farms and factories for a more sustainable world. Jobs: https://jobs.cradle.bio
early stageBiotechnology
2021
Seed Investor
Nov 2021
Seqera is on a mission to simplify complex data analysis pipelines in the cloud. We provide software that enables developers and data scientists to create and deploy data applications in any environment. Our core, open-source technology Nextflow transforms the building of massively scalable and distributed computing solutions. Seqera is now empowering customers across pharma, genomics and biotech to break with the status quo of closed-platforms and custom scripts to embrace the future of cloud.
Seed Investor
Nov 2021
Lindus is an Accountable Research Organization, engineered to give biotech and pharmaceutical sponsors confidence and control to generate clinical data on time and on budget. In the last 3 years, Lindus has executed over 45 full-scope trials across cardiometabolic, respiratory, psychiatry, dermatology, womens health, and diagnostics. Behind each study is an integrated model spanning feasibility, central enrollment infrastructure, and flexible site models. Trials run on Citrus™, an AI-native trial operating system, and are governed by performance-based contracts with milestone-based payments. 82% of Lindus executed trials completed enrollment on or ahead of our proposed timeline. The company is backed by Dr. Bob Langer, Peter Thiel, and Dr. Tim Garnett.
Show all 9 entries ↓
Investment activity
2021–2024 · 7 investments
202142022220241
Recent (last 2 years)Earlier